Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

PD-L1 Expression: Predicting Immunotherapy Response in Urothelial Carcinoma

News

Researchers Construct Prognostic Nomogram for Use in Patients With Bladder Cancer and Lung Metastasis

Medical Literature

Identifying Key Genes in Bladder Cancer May Improve Outcomes With Immunotherapy

Medical Literature

DNA Repair Biomarkers as Prognostic Indicators in Patients With Bladder Cancer

News

Can the Antidepressant Fluoxetine Promote Sensitivity to Cisplatin in Bladder Cancer?

News

Surgical Strategies to Reduce Recurrence of Upper Tract Urothelial Carcinoma

Medical Literature

Prognostic Risk Score Model for Bladder Tumors Based on Immunotherapy-Related Long Noncoding RNAs

Thomas Flaig, MD, on the Role of Antibody-Drug Conjugates in Advanced Urothelial Cancer

Aristotelis Bamias, MD, on Atezolizumab Monotherapy vs Chemotherapy for Urothelial Carcinoma

View More

Advertisement

JNCCN Spotlights

(UPDATE) Sacituzumab Govitecan-hziy

(UPDATE) Enfortumab Vedotin-ejfv

Adjuvant Nivolumab

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

Ongoing Trial to Evaluate Erdafitinib in FGFR3-Mutated Non–Muscle-Invasive Bladder Cancer

Researchers Explore How Sexual Diversity May Impact Bladder Cancer

The Changing Treatment Landscape in Urothelial Carcinoma: Focus on PARP Inhibitors

$11.2 Million Grant From NCI to Fund Research on Sex Differences in Bladder Cancer

ASCO 2023: Some Patients With Metastatic Urothelial Cancer May Benefit From Erdafitinib Over Chemotherapy

ASCO 2023: 5-Year Survival Data on Perioperative Chemotherapy in Muscle-Invasive Bladder Cancer

Surgical Strategies to Reduce Recurrence of Upper Tract Urothelial Carcinoma

ASCO 2023: Comparing Types of Lymphadenectomy in Surgical Treatment of Muscle-Invasive Urothelial Cancer

View More

Advertisement

Published

Medical Literature

Is Neoadjuvant Standard of Care for Muscle-Invasive Bladder Cancer Appropriate for Older Patients?

Risk Factors for Early Recurrence After Transurethral Resection of Bladder Cancer

Case Report Focuses on Elevated HCG Level and Risk of Urothelial Carcinoma

Improving Preoperative Treatment Plans in Bladder Cancer: Focus on Cystoscopic Parameters

View More

Ongoing

CE Activities

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Management of Nonmetastatic Urothelial Bladder Cancer

Archived Monthly Oncology Tumor Boards: Treatment of Patients with Bladder and Upper Tract Urothelial Cancer

Breakfast with the Investigators: Urothelial Bladder Cancer

View More

Available

Clinical Trials

A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy

Study of CG0070 Given in Patients With Non-MIBC, Unresponsive to Bacillus-Calmette-Guerin

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.